NCT04965753 - FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

December 4, 2023

Study Completion Date

December 4, 2023

Conditions

Advanced Synovial Sarcoma

Interventions

DRUG

FHD-609

FHD-609 as a single, intravenously administered agent given twice-weekly (BIW). Alternative dosing regimens may be evaluated.

Trial Locations (12)

Memorial Sloan Kettering Cancer Center, New York

Istituto Nazionale dei Tumori, Milan

University of Miami Health System, Miami

Sarah Cannon Research Institute, Nashville

Centre Leon Berard, Lyon

MD Anderson Cancer Center, Houston

City of Hope, Duarte

Institut Gustave Roussy, Villejuif

Fred Hutchinson Cancer Research Center, Seattle

Massachusetts General Hospital, Boston

Dana-Farber Cancer Institute, Boston

Hospital Universitari Vall d'Hebron, Barcelona